German Trading, page-678

First 678 Last

Share
Profile

Follow
b!ll

2,146 Posts.

508

08/09/21

15:44

Post #: 55925313
Share

Originally posted by Bullant: ↑

nice B!ll you are a good man. happy to play again if you like? your terms.....

i was going to stay silent on the EGR thing but now we are chatting thought i share with you my thoughts.
the EGR mou with FYI is nothing more than an R&D experiment. the add value downstream opportunity is very miss leading when it is actually R&D + EGR is basically an experiment in itself. the EGR md is number 1 shareholder in FYI, i am ok with that but this doesnt make the situation very compelling. more important i asked somebody a lot smarter battery person and his thoughts after reading the EGR/FYI comment is " I’m not sure they understand this technology. The doping/coating of HPA onto graphite and siliconised graphite particles is a chemical process not a physical process." he had more to say but you get the idea.

also amusing is that EGR has the same HC setup as FYI regarding thread commentary. there are few "trolls, downrampers etc" as they get called because people dislike their comments. one of the pumpers has a footnote "Invest in EGR = Sleep Like a Baby". In all my HC history i have never come across these people until very recent. fine to be a momentum chaser, make money, but some of us like investing in juniors and seeing it out to maybe something bigger. in respect to the later people, dont shoot them down when they make a fundamental comment you may not like.

Alcoa will see this like a hot knife through butter, but for now it feeds the machine. we see, your call B!ll?

Expand

I don’t think they woke up this morning and come up with the idea - I could be wrong as my track record would suggest.

Do you want to bet I get my renovations and pool finished by Christmas?

FYI Price at posting: 78.0¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 25 more messages in this thread...

First 678 Last

Add CCM (ASX) to my watchlist

(20min delay)
Last 6.8¢		Change 0.001(1.49%)		Mkt cap ! $25.22M

Open	High	Low	Value	Volume
6.7¢	6.8¢	6.7¢	$7.47K	111.1K

Buyers (Bids)

No.	Vol.	Price($)
1	20000	6.2¢

Sellers (Offers)

Price($)	Vol.	No.
6.7¢	25000	1

View Market Depth

No.	Vol.	Price($)
1	20000	0.062
1	16666	0.060
1	14500	0.058
1	180	0.057
1	9109	0.055

Price($)	Vol.	No.
0.067	25000	1
0.068	68912	1
0.069	313335	5
0.070	274901	2
0.077	14000	1

Last trade - 14.40pm 07/10/2024 (20 minute delay)

CCM (ASX) Chart

German Trading, page-678

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

German Trading, page-678

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News